New data from Worldpanel by Numerator showed that households containing at least one person using GLP-1 medications, including Wegovy and Mounjaro, spent approximately £389 less on groceries than comparable households during the year after treatment began.

The findings suggest that the expanding use of medicines designed to regulate appetite and support weight management is beginning to produce measurable changes in household purchasing patterns.

The proportion of British households with at least one GLP-1 medication user increased from 6.3% in February 2026 to 8.5% in August. The estimated reduction in national grocery spending consequently rose from £780 million in June to approximately £1 billion in the latest assessment.

The research also identified a significant increase in male participation. The number of men using GLP-1 medications rose from approximately 440,000 in February to 830,000 in August, increasing their share of users from 23% to 32%.

The growing availability of oral treatments has contributed to wider adoption. GLP-1 pills received approval from the UK's Medicines and Healthcare products Regulatory Agency in June, with pills accounting for 11.2% of users by August.

Worldpanel senior consultant Nishita Pattni said adoption had accelerated significantly between February and August, with the convenience of daily tablets expected to attract additional consumers.

The development presents new challenges for supermarkets, packaged food manufacturers and consumer goods companies whose revenues depend heavily on household food purchasing volumes.

Retailers may need to reconsider product development, portion sizes and promotional strategies as demand patterns evolve. Businesses could also face increasing pressure to adapt their product portfolios to consumers seeking smaller portions and different nutritional options.

However, the figures do not establish that every household using weight-loss medication will reduce spending by the same amount. Individual consumption patterns, treatment duration and household circumstances remain important factors.

The findings nevertheless indicate that pharmaceutical innovation is extending beyond healthcare, creating potential structural changes in the food and grocery market.

For British retailers, understanding the commercial implications of rising GLP-1 adoption could become increasingly important as these treatments reach a larger share of the population.